Vertex Pharmaceuticals/$VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6,100
Website
VRTX Metrics
BasicAdvanced
$117B
-
-$3.84
0.51
-
Price and volume
Market cap
$117B
Beta
0.51
52-week high
$519.68
52-week low
$377.85
Average daily volume
1.2M
Financial strength
Current ratio
2.646
Quick ratio
2.116
Long term debt to equity
9.997
Total debt to equity
9.997
Interest coverage (TTM)
189.98%
Profitability
EBITDA (TTM)
4,584.4
Gross margin (TTM)
53.09%
Net profit margin (TTM)
-8.91%
Operating margin (TTM)
39.71%
Effective tax rate (TTM)
-229.41%
Revenue per employee (TTM)
$1,820,000
Management effectiveness
Return on assets (TTM)
11.77%
Return on equity (TTM)
-5.64%
Valuation
Price to revenue (TTM)
10.602
Price to book
7.12
Price to tangible book (TTM)
7.84
Price to free cash flow (TTM)
-93.544
Free cash flow yield (TTM)
-1.07%
Free cash flow per share (TTM)
-4.884
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-124.93%
3-year revenue growth (CAGR)
11.78%
10-year revenue growth (CAGR)
33.87%
3-year earnings per share growth (CAGR)
-25.99%
10-year earnings per share growth (CAGR)
2.58%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·2 hours ago
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
Business Wire·3 weeks ago
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $117B as of August 01, 2025.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 0 as of August 01, 2025.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.